Arvinas unveils first efficacy signal for targeted protein degradation, points to opportunity in resistant cancers

Arvinas’ top-line ASCO data provides the first evidence that targeted protein degraders can benefit patients, in particular those whose tumors have become resistant to standard therapies.

Founded by targeted degradation pioneer Craig Crews in 2013, Arvinas Inc. (NASDAQ:ARVN) has long been the torchbearer for the rapidly growing space. In October, the company presented the first clinical data for targeted protein degraders, showing oral bioavailability for its two lead PROTACs (proteolysis targeting chimeras). ARV-110 and ARV-471 tag the androgen receptor and estrogen receptor for degradation by the proteasome, respectively (see “Arvinas Clears Key Hurdle”). ...